Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Colorcon
Merck
McKesson
Express Scripts

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,216,997

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,216,997
Title:Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Inventor(s): Seehra; Jasbir (Lexington, MA), Pearsall; Robert Scott (Woburn, MA), Kumar; Ravindra (Acton, MA)
Assignee: Acceleron Pharma, Inc. (Cambridge, MA)
Application Number:12/856,420
Patent Claims:1. A method for increasing red blood cell levels or treating anemia in a patient, the method comprising administering to a patient in need thereof: (a) an erythropoietin receptor activator, wherein the activator is an agent that i) increases proliferation of immature erythroblasts, ii) increases differentiation of immature erythroblasts, and/or iii) decreases apoptosis in erythroid progenitor cells; and (b) a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1, and wherein the polypeptide comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 1, wherein the polypeptide binds to GDF11; and wherein the erythropoietin receptor activator and the polypeptide are administered in an effective amount.

2. The method of claim 1, wherein the administered amount of erythropoietin receptor activator is by itself ineffective in increasing red blood cell levels in the patient even though combined treatment is effective.

3. The method of claim 1, wherein the administered amount of polypeptide is by itself ineffective in increasing red blood cell levels in the patient even though combined treatment is effective.

4. The method of claim 1, wherein the erythropoietin receptor activator is an erythropoiesis-stimulating agent.

5. The method of claim 4, wherein the erythropoiesis-stimulating agent is an EPO-based derivative selected from a group consisting of: a. epoetin alfa b. epoetin beta (NeoRecormon) c. epoetin delta (Dynepo) d. epoetin omega e. darbepoetin alfa (Aranesp) f. methoxy-polyethylene-glycol epoetin beta (Micera), and g. synthetic erythropoiesis protein (SEP).

6. The method of claim 1, wherein the erythropoietin receptor activator is an erythropoietin receptor agonist chosen from a group consisting of: a. a peptidic erythropoietin mimetic b. an erythropoietin receptor extended-duration limited agonist c. a fusion protein comprising an erythropoietin mimetic domain and an Fc domain d. an agonistic antibody targeting the erythropoietin receptor and e. a multimeric peptidic erythropoietin mimetic.

7. The method of claim 1, wherein the patient has anemia associated with a kidney disorder.

8. The method of claim 7, wherein the patient has anemia associated with chronic kidney disease.

9. The method of claim 1, wherein the patient has anemia associated with a chemotherapy treatment.

10. The method of claim 9, wherein the chemotherapy treatment is a taxane.

11. The method of claim 1, wherein the patient has anemia as a consequence of blood loss.

12. The method of claim 1, wherein the polypeptide comprises an amino acid sequence corresponding to amino acids 29-109 of SEQ ID NO:1.

13. A method for increasing red blood cell levels or treating myelodysplastic syndrome (MDS) in a patient, the method comprising administering to a patient in need thereof: (a) a therapeutic agent for treating MDS; and (b) a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1, and wherein the polypeptide comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 1, wherein the polypeptide binds to GDF11; wherein the therapeutic agent for treating MDS and the polypeptide are administered in an effective amount.

14. The method of claim 13, wherein the therapeutic agent for treating MDS is selected from the group consisting of: thalidomide, lenalidomide, azacitadine, decitabine, an erythropoietin receptor activator, erythropoietins, deferoxamine, antithymocyte globulin, filgrastrim (G-CSF) and an erythropoietin signaling pathway agonist.

15. The method of claim 14, wherein the therapeutic agent for treating MDS is an erythropoietin receptor activator that i) increases proliferation of immature erythroblasts, ii) increases differentiation of immature erythroblasts, and/or iii) decreases apoptosis in erythroid progenitor cells.

16. The method of claim 15, wherein the administered amount of erythropoietin receptor activator is by itself ineffective in increasing red blood cell levels even thought combined treatment is effective.

17. The method of claim 13, wherein the administered amount of polypeptide is by itself ineffective in increasing red blood cell levels in the patient even though combined treatment is effective.

18. The method of claim 15, wherein the erythropoietin receptor activator is an erythropoiesis-stimulating agent and wherein the erythropoiesis-stimulating agent is selected from a group consisting of: a. epoetin alfa b. epoetin beta (NeoRecormon) c. epoetin delta (Dynepo) d. epoetin omega e. darbepoetin alfa (Aranesp) f. methoxy-polyethylene-glycol epoetin beta (Micera), and g. synthetic erythropoiesis protein (SEP).

19. The method of claim 15, wherein the erythropoietin receptor activator is an erythropoietin receptor agonist, wherein the erythropoietin receptor agonist is chosen from a group consisting of: a. a peptidic erythropoietin mimetic b. an erythropoietin receptor extended-duration limited agonist c. a fusion protein comprising an erythropoietin mimetic domain and an Fc domain d. an agonistic antibody targeting the erythropoietin receptor, and e. a multimeric peptidic erythropoietin mimetic.

20. The method of claim 13, wherein the polypeptide comprises an amino acid sequence corresponding to amino acids 29-109 of SEQ ID NO:1.

Details for Patent 8,216,997

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; MULTIDOSE 103234 002 1989-06-01   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; MULTIDOSE 103234 003 1989-06-01   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 004 1989-06-01   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 005 1989-06-01   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.